NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
Objectives: Adults exposed to the Bacillus Calmette-Guérin (BCG) vaccine demonstrate a reduced incidence of Parkinson's disease (PD). This retrospective study evaluated whether early-life BCG vaccination predicts a long-term reduction in PD incidence during aging. Methods: Published age-adjusted incidence rates (AAIRs) of PD (2002-2021) were structured into single-age birth cohorts. Missing values were calculated via interpolation and shuffling simulations. Cohorts were categorized into three historical BCG policy periods: unvaccinated controls (born 1945-1949), vaccinated at age 12 (born 1950-1954), and vaccinated as newborns (born 1955-1959). AAIRs were compared at identical cross-sectional ages (57 and 62 years), applying an environmental drift penalty to control for temporal improvements. Results: In men, the age 12 policy showed a 21.8% AAIR reduction at age 57, which attenuated to 4.4% by age 62; the newborn policy showed a sustained reduction (25.8% at age 57; 20.4% at age 62). In women, the age 12 policy yielded a 67.5% reduction at age 57 (33.1% at age 62), while the newborn policy showed a 56.8% reduction at age 57 (44.0% at age 62). Conclusions: Early-life BCG vaccination is associated with reduced later-life PD incidence, displaying a profound sex-dependent effect favoring females. Newborn vaccination provides long-term resistance as well.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.